TD Cowen Maintains Immunome(IMNM.US) With Buy Rating
TD Cowen Sticks to Its Buy Rating for Immunome (IMNM)
Wedbush Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $33
Leerink Partners Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $38
Buy Rating Affirmed on Immunome: Promising Clinical Trials and Strategic Growth Prospects
Wedbush Reiterates Outperform on Immunome, Maintains $33 Price Target
Immunome Price Target Cut to $23.00/Share From $27.00 by Piper Sandler
TD Cowen Maintains Immunome(IMNM.US) With Buy Rating
Piper Sandler Maintains Immunome(IMNM.US) With Buy Rating, Cuts Target Price to $23
Immunome Analyst Ratings
Piper Sandler Sticks to Their Buy Rating for Immunome (IMNM)
TD Cowen Sticks to Its Buy Rating for Immunome (IMNM)
Immunome (IMNM.US) was first covered by Piper Sandler, which gave it an increase rating, and the target price was $27.00.
Immunome Analyst Ratings
Piper Sandler Initiates Coverage On Immunome With Overweight Rating, Announces Price Target of $27
Immunome's Promising Pipeline and Strategic Positioning Affirm Buy Rating
TD Cowen Sticks to Their Buy Rating for Immunome (IMNM)
Immunome Analyst Ratings
JPMorgan Starts Immunome With Overweight Rating, $24 Price Target
Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Dyne Therapeutics (DYN) and Dexcom (DXCM)